• Dementia is a major public health concern of the 21st century and one of the leading causes of morbidity and mortality in aging population • Alzheimer’s disease (AD) is the most common form of dementia that attributes to 60-80% (2/3) of all dementia cases occur over the age of 65 years UNDERSTANDING ALZHEIMER'S DISEASE Neurodegenerative Disease: Most Common Form of Dementia: Typical Onset: Early. [...] Comparison of plasma pTau181 between Aβ- and Aβ+ (in HC, MCI and AD at timepoint T1) and between HC, MCI and AD at three follow-up timepoints (T1, T2 and T3) Comparison of plasma GFAP between Aβ- and Aβ+ (in HC, MCI and AD at timepoint T1) and between HC, MCI and AD at three follow-up timepoints (T1, T2 and T3) Comparison of plasma NFL between Aβ- and Aβ+ (in HC, MCI and AD at timepoint T1) and be. [...] Australia’s Growing Dementia Problem 2nd leading cause of death of Australians Leading cause of death in Australian women • Currently (2022), there are 487,500 people living with dementia in Australia, and it’s estimated that almost 1.6 million people are involved in the care of these people • The number of people with dementia is expected to increase to 1,076,000 by 2058 (Dementia.org.au/statisti. [...] The FINGER STUDY The Finland FINGER (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability) study showed that the combination of regular exercise, brain training exercises, adherence to the MIND diet, and regular monitoring of vascular risk factors significantly benefits cognition. [...] site of damage/infection) but can involve the lining of blood vessels and many internal organs and systems • Neuroinflammation: Specifically, inflammation of the central nervous system including the brain, and in the case of AD is a response to the build up Aβ, a small protein that is toxic if not removed It is conceivable that the protective role of MeDi against cognitive decline is mediated by t.
Related Organizations
- Pages
- 103
- Published in
- Canada
Table of Contents
- Slide 1 1
- Slide 2 2
- Slide 3 3
- Slide 4 4
- Slide 5 5
- Slide 6 6
- Slide 7 7
- Slide 8 8
- Slide 9 9
- Slide 10 10
- Slide 11 11
- Slide 12 12
- Slide 13 13
- Slide 14 14
- Slide 15 15
- Slide 16 16
- Slide 17 17
- Slide 18 18
- Slide 19 19
- Slide 20 20
- Slide 21 21
- Slide 22 22
- Slide 23 23
- Slide 24 24
- Slide 25 25
- Slide 26 26
- Slide 27 27
- Slide 28 28
- Slide 29 29
- Slide 30 30
- Slide 31 31
- Slide 32 32
- Slide 33 33
- Slide 34: Current Gold Standard Markers for AD 34
- Slide 35 35
- Slide 36 36
- Slide 37 37
- Slide 38 38
- Slide 39 39
- Slide 40 40
- Slide 41 41
- Slide 42 42
- Slide 43 43
- Slide 44 44
- Slide 45 45
- Slide 46 46
- Slide 47 47
- Slide 48 48
- Slide 49 49
- Slide 50 50
- Slide 51 51
- Slide 52 52
- Slide 53 53
- Slide 54 54
- Slide 55 55
- Slide 56 56
- Slide 57 57
- Slide 58: Australia’s Growing Dementia Problem 58
- Slide 59: Background To The AU-ARROW Study 59
- Slide 60 60
- Slide 61: AU-ARROW Clinical Study Design 61
- Slide 62 62
- Slide 63 63
- Slide 64 64
- Slide 65 65
- Slide 66 66
- Slide 67 67
- Slide 68 68
- Slide 69 69
- Slide 70 70
- Slide 71 71
- Slide 72 72
- Slide 73 73
- Slide 74 74
- Slide 75 75
- Slide 76 76
- Slide 77 77
- Slide 78 78
- Slide 79 79
- Slide 80 80
- Slide 81 81
- Slide 82 82
- Slide 83 83
- Slide 84 84
- Slide 85 85
- Slide 86 86
- Slide 87 87
- Slide 88 88
- Slide 89 89
- Slide 90 90
- Slide 91 91
- Slide 92 92
- Slide 93 93
- Slide 94 94
- Slide 95 95
- Slide 96 96
- Slide 97 97
- Slide 98 98
- Slide 99 99
- Slide 100 100
- Slide 101 101
- Slide 102 102
- Slide 103 103
